-
Most Recent
Uncategorized
The Growing Power of Fintech
Fintech is a great illustration of the Technochasm at work … one leading fintech company’s returns are dominating the S&P … a simple, one-click way…
A Move Into Novavax Stock Makes Sense Ahead of Several Near-term Catalysts
NVAX is a disappointing stock because of manufacturing issues and filing delays hampering progress, but there are brighter days ahead for the vaccine maker.
With a Little Detective Work, You Won’t Get Duped Like Goldman Sachs Almost Was
When private companies make dubious claims, always do your due diligence; as Columbo puts it, "just one more thing..."
Jump Head-First Into a Recent IPO With GitLab
You don't have to be a software developer to seize the opportunity with GTLB stock as a geek-friendly up-and-comer makes its public debut.
Weekly Upgrades and Downgrades
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fundamental health, I decided to revise my Portfolio Grader recommendations for 129 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly.
Post-earnings QuantumScape Stock Drop Offers Ancillary EV Opportunity
QS does not justify its valuation, but it has the potential to break out as has been the case after every recent QuantumScape earnings release.
Still Acting Like SPAC, Rocket Lab USA ‘Pops on News, Flops on Booze’
Although RKLB stock is a scientifically intriguing idea, Rocket Lab USA's market performance is reminiscent of other SPACs, which isn’t encouraging.
GameStop Could Still Fall, Even if Stocks Overall Stay Steady
Still at risk of big capitulation, with little hope of experiencing even one last spike, your best move remains the same: steer clear of GME stock.
Short Squeeze Stocks: PTGX, AGC and 3 Others Experts Think Are Ready to Pop
Here are five short squeeze stocks many investors are putting on their radar right now as a result of higher short interest and borrow fees.
Weekly Upgrades and Downgrades
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fundamental health, I decided to revise my Portfolio Grader recommendations for 129 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly.
While Much Riding on FDA Nod, Novavax Fortunes Are More Than Just Covid
The FDA approval is a near term catalyst that will take NVAX stock to new highs over the coming months. Buy NVAX stock in the dip.
Cash-burning Canoo Can’t Seem To Join Peers on EV Production Bandwagon
GOEV stock isn't going to amount to much at this rate. Investors should understand that its peers are pulling in front as you read this.
Chinese Government Scrutiny Makes DiDi Global Stock a Name to Avoid
DIDI stock faces immense regulatory woes which will continue to impact the company's performance for the foreseeable future. DiDi Global is a name to avoid.
Crypto Miner SOS Has One Thing Going for It but Even That Won’t Be Enough
SOS stock offers the ability to invest in cryptos without doing so directly but such an argument is not exclusive to the company.
Strong User Growth Should Stoke SoFi Stock Gains For Long-Term Holders
Buying SOFI stock below $20 is a great bet as it has the potential and ability to soar higher in the coming months.
As Bitcoin Rages Higher, Smart Crypto Money Should Diversify Into Floki Inu
While Bitcoin has attracted most of the headlines, the risk-reward profile now favors speculative digital assets like Floki Inu.
Tilray Stock Is Still Poised to Turn Over a New Leaf
U.S. legalization, and Tilray's global expansion efforts could enable TLRY stock to climb significantly above its current levels.
Weekly Upgrades and Downgrades
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fundamental health, I decided to revise my Portfolio Grader recommendations for 129 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly.
